Autopsy report · NCT05184283

Utilization of MAsS in Patients Undergoing LT for HCC

“Discontinued by Amra Medical due to funding.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Columbia University

Sponsor type

University, hospital or other

Conditions

NAFLD; Hepatocellular Carcinoma; Liver Diseases; Liver Cancer; Cirrhosis, Liver; Hepatitis C

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• Evaluation of MST-188 in Acute Lower Limb Ischemia
  “Program discontinued to persue alternate indications.” (65% match in meaning)
• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (63% match in meaning)
• Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)
  “Funding for this study has been discontinued.” (62% match in meaning)
• Testing the Safety of CB-5339 in Patients With Cancer
  “Other - Clinical development of the agent has been discontinued” (61% match in meaning)
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
  “Study discontinued due to futility.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.